ASCO Solid Tumors 2022 – Ian Chau
Ian Chau summarizes the notable efficacy and safety data obtained with nivolumab plus chemotherapy or ipilimumab versus chemo as 1L treatment for advanced ESCC in the CheckMate 648 trial and explains the role of EGFR inhibitors in the treatment of ESCC, especially in combination with radiation. He focuses on the treatment paradigm in advanced/metastatic ESCC and how it might change in the near future while also explaining the barriers to implementing precision oncology in the setting of ESCC.
Here is the full ASCO 2022 Solid Tumors report.
More posts
New therapeutic options being currently investigated in advanced or metastatic colorectal cancer
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, and it is the fourth most frequent cancer diagnosis.A current treatment option for RAS and BRAF wild-type (WT) metastatic colorectal cancer (mCRC) is the chemotherapy doublet (FOLFOX/FOLFIRI) with an anti-EGFR monoclonal antibody (cetuximab or panitumumab).
An update and future directions in advanced gastric or gastrointestinal junction cancer (G/GEJC)
With more than 1 million newly diagnosed cases in 2020, gastric cancer (GC) is the fifth most frequent cancer; it was also the third leading cause of cancer-related death worldwide. Gastroesophageal junction (GEJ) cancer concerns a form of gastric cancer developing around the digestive tract where esophagus and stomach connect; in the last years, the prevalence of GEJ constantly increased.
Innovative combinations in esophageal squamous cell carcinoma
Each year, esophageal cancer (EC) is responsible for more than half a million deaths worldwide. Among them, esophageal squamous cell carcinoma (ESCC) accounts for the vast majority (~ 85 %) of EC incidences . At diagnosis, 70 % of ESCC is unresectable [3] and the 5-year survival rate is limited (30 % - 40 %). Patients with advanced or metastatic ESCC have a poor prognosis; their overall survival (OS) after standard first-line chemotherapy is limited to less than a year and other treatment options are scarce.
Novel agents or combinations in recurrent or metastatic nasopharyngeal cancer
Nasopharyngeal cancer (NPC) is a rare malignancy with an incidence of approximately 133,000 annually worldwide, resulting in about 80,000 deaths per year. Whereas early-stage and locally advanced NPC have a good prognosis, treatment of recurrent or metastatic nasopharyngeal cancer is a challenging; it is thus associated with a poor prognosis, especially in patients who have failed two or more lines of systemic therapy, with a median progression-free survival (mPFS) of seven months and median overall survival (mOS) of 22 months.
Preface ASCO Solid Tumor 2022
After 2 years of the COVID-19 pandemic, the Annual Meeting of the American Society of Clinical Oncology (ASCO), was held in Chicago, USA, and virtually from 3rd–7th June 2022.As always, the very much-anticipated event brought leading experts from across the globe together to learn and discuss the groundbreaking updates and scientific advancements which were covered in more than 2,000 abstracts, along with 85 livestream sessions, and more than 2,500 poster presentations.